title: Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck.
abstract: We have previously reported that the cyclin D1 (CCND1) GG870 genotype was associated with poorly differentiated tumors and reduced disease-free interval in patients with squamous cell carcinoma of the head and neck (SCCHN). We have now examined the association of this and a second CCND1 polymorphism with gene expression and outcome in SCCHN patients. Analysis of a CCND1 G/C1722 polymorphism revealed that CCND1 CC1722 genotype was associated with poorly differentiated tumors [P = 0.005; odds ratio (OR), 5.7; 95% CI, 1.7 to 19.2), and reduced disease-free interval (P = 0.003; Hazard Ratio (HR), 7.3; 95% CI, 1.1 to 27.2.) independently from the influence of CCND1 GG870 genotype. Patients whose tumors were negative for cyclin D1 were associated with reduced disease-free interval (P = 0.028; HR, 4.1; 95% CI, 1.4 to 14.2). Although G/C1722 genotypes were not associated with expression, we found a significant trend between reduced expression of cyclin D1 in patients with the CCND1 GG870 genotype (P = 0.04). Splicing of CCND1 mRNA in head and neck tissues was modulated by CCND1 A/G870 alleles, thus CCND1 transcript a was spliced equally from CCND1 A870 and G870 alleles, whereas CCND1 transcript b was spliced mainly from the CCND1 A870 allele. Our analysis has also identified differences in cyclin D1 genotype and protein expression and the pathogenesis of SCCHN in males and females. Thus, CCND1 CC1722 genotype was more common in female patients (P = 0.019; OR, 3.3; 95% CI, 1.3 to 10) and cyclin D1 expression was more frequent (chi-square1, 3.96; P = 0.046) and at higher levels (P = 0.004) in tumors from female patients. In summary, our data show that the two CCND1 polymorphic sites are independently associated with tumor biology and clinical outcome. CCND1 A/G870 alleles affect gene expression in head and neck tissues. We also provide preliminary evidence that the molecular genetics of SCCHN development may be influenced by patient gender.
authors.affiliation: Centre for Cell and Molecular Medicine, University of Keele School of Postgraduate Medicine, North Staffordshire Hospital, Stoke-on-Trent, United Kingdom.
authors.forename: S L
authors.initials: SL
authors.lastname: Holley
authors.forename: G
authors.initials: G
authors.lastname: Parkes
authors.forename: C
authors.initials: C
authors.lastname: Matthias
authors.forename: U
authors.initials: U
authors.lastname: Bockmühl
authors.forename: V
authors.initials: V
authors.lastname: Jahnke
authors.forename: K
authors.initials: K
authors.lastname: Leder
authors.forename: R C
authors.initials: RC
authors.lastname: Strange
authors.forename: A A
authors.initials: AA
authors.lastname: Fryer
authors.forename: P R
authors.initials: PR
authors.lastname: Hoban
mesh_terms: D000483:Alleles; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism*; D019938:Cyclin D1 / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D005838:Genotype; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D012727:Sex Characteristics
chemical_list: D019938:Cyclin D1